



Li et al. Cardiovascular Diabetology 2013, 12:141
http://www.cardiab.com/content/12/1/141ORIGINAL INVESTIGATION Open AccessThe role of profilin-1 in endothelial cell injury
induced by advanced glycation end products
(AGEs)
Zhenyu Li1, Qiaoqing Zhong2, Tianlun Yang3, Xiumei Xie1 and Meifang Chen1*Abstract
Background: Accumulation of advanced glycation end products (AGEs) in the vasculature triggers a series of
morphological and functional changes contributing to endothelial hyperpermeability. The reorganisation and
redistribution of the cytoskeleton regulated by profilin-1 mediates endothelial cell contraction, which results in
vascular hyperpermeability. This study aimed to investigate the pivotal role of profilin-1 in the process of
endothelial cell damage induced by AGEs.
Methods: Human umbilical vein endothelial cells (HUVECs) were incubated with AGEs. The mRNA and protein
expression of profilin-1 was determined using real-time PCR and western blotting analyses. The levels of
intercellular adhesion molecule-1 (ICAM-1), nitric oxide (NO) and reactive oxygen species (ROS), as well as the
activities of nuclear factor-κB (NF-κB) and protein kinase C (PKC), were detected using the appropriate kits. The
levels of asymmetric dimethylarginine (ADMA) were determined using HPLC. The distribution of the cytoskeleton
was visualised using immunofluorescent staining.
Results: Compared with the control, incubation of endothelial cells with AGEs (200 μg/ml) for 4 or 24 h significantly
up-regulated the mRNA and protein expression of profilin-1, markedly increased the levels of ICAM-1 and ADMA and
decreased the production of NO (P<0.05, P<0.01), which was significantly attenuated by pretreatment with DPI (an
antioxidant), GF 109203X (PKC inhibitor) or BAY-117082 (NF-κB inhibitor). DPI (10 μmol/L) markedly decreased the
elevated levels of ROS induced by AGEs (200 μg/ml, 24 h); however, GF 109203X (10 μmol/L) and BAY-117082 (5 μmol/L)
exhibited no significant effect on the formation of ROS by AGEs. Immunofluorescent staining indicated that AGEs
markedly increased the expression of profilin-1 in the cytoplasm and the formation of actin stress fibres, resulting in the
rearrangement and redistribution of the cytoskeleton. This effect was significantly ameliorated by DPI, GF 109203X,
BAY-117082 or siRNA treatment of profilin-1. Incubation with DPI and GF 109203X markedly inhibited the activation of
PKC triggered by AGEs, and DPI and BAY-117082 significantly decreased the activity of NF-κB mediated by AGEs.
Disruption of profilin-1 gene expression attenuated the extent of endothelial abnormalities by reducing ICAM-1 and
ADMA levels and elevating NO levels (P<0.05, P<0.01), but this disruption had no effect on the activities of NF-κB and
PKC (P>0.05).
Conclusions: These findings suggested that profilin-1 might act as an ultimate and common cellular effector in the
process of metabolic memory (endothelial abnormalities) mediated by AGEs via the ROS/PKC or ROS/NF-қB
signalling pathways.
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Diabetes mellitus (DM) is a serious and rapidly growing
disease, and diabetes-related vascular complications are
major causes of patient disability and death. Large-scale
clinical studies have confirmed that early intensive blood
glucose control can reduce the incidence of diabetic
microvascular and macrovascular complications. However,
for patients with chronic long-term hyperglycaemia, des-
pite strict future long-term glycaemic control, diabetes-
related vascular complications remain or can develop.
This phenomenon is known as “metabolic memory” or
“hyperglycaemia memory.” There is growing evidence that
faster-generated advanced glycation end products (AGEs)
in the conditions of long-term high glucose may be a uni-
fying explanation for this phenomenon [1]. Previous stud-
ies have demonstrated that AGEs are involved in the
pathogenesis of endothelial dysfunction in diabetic vascu-
lar complications, and its levels in diabetic patients are
highly correlated with the severity of macrovascular and
microvascular complications [2,3]. However, the mechan-
ism of “metabolic memory” mediated by AGEs has not
been fully elucidated to date. The direct effects of AGEs
include protein glycation and crosslinking, which affect
normal protein physiological functions. In addition, this
process is prolonged and irreversible. There is a growing
body of evidence that AGEs mediate “metabolic memory”,
primarily via indirect pathways via its receptors (receptor
for advanced glycation end products, RAGE) [4]. Indeed,
binding of AGEs to RAGE produces the excess formation
of reactive oxidative species (ROS) independent of actual
glucose, which subsequently activates protein kinase C
(PKC) and the redox-sensitive transcription factor nuclear
factor kappa B (NF-κB) via intracellular signalling cascade
reactions. This activation subsequently initiates the ex-
pression of a variety of diabetes-related genes and RAGE
[5]. Thus, self-maintaining conditions linked to AGE for-
mation demonstrate that AGEs can conceivably contribute
to “metabolic memory.”
Profilin-1 as an actin-binding protein is a class of small
molecule proteins (12 to 15 KD) and is widely distributed
in various types of cells with highly conserved sequences.
This plays an important role in the regulation of actin
polymerisation in a number of motility functions. The
reorganisation and redistribution of the cytoskeleton, par-
ticularly actin proteins, forms a pathological basis for
endothelial cell contraction and increased vascular perme-
ability, which contributes to endothelial abnormalities and
vascular disease [6]. Under pathological conditions, such
as diabetes or atherosclerosis (AS), profilin-1 levels were
increased in atherosclerotic lesions, the aorta or in serum.
It was recently reported that profilin-1 overexpression
triggered indicators of endothelial dysfunction and attenu-
ated the expression of profilin-1 conferred protection from
AS in vivo [7,8]. In addition, Romeo et al. reported thatprofilin-1 and low density lipoprotein (LDL) was down-
stream molecules mediating diabetic endothelial dysfunc-
tion, and revealed that the endothelial damage triggered
by the profilin-1 pathway in diabetes and in lipid oxidation
was surprisingly similar [7,9]. Thus, we hypothesized that
profilin-1 may be a common and ultimate pathway in
endothelial cell injuries, and blockade of profilin-1-medi-
ated biological effects may help to prevent the occurrence
of endothelial abnormalities and vascular disease.
Recent studies have demonstrated that incubation of
endothelial cells with AGEs caused a significant increase
in endothelial permeability via cytoskeletal alterations and
actin rearrangement [10,11]. Due to the pivotal role of
profilin-1 in the reorganisation and redistribution of actin,
we propose that profilin-1 may be involved in metabolic
memory mediated by AGEs as an ultimate pathway in
endothelial injury. Thus, the present study aimed to eluci-
date the role of profilin-1 in endothelial injury mediated
by AGEs and its underlying signal transduction pathways.
Materials and methods
Chemicals and reagents
Human umbilical vein endothelial cells (HUVEC12,
ATCC,CRL-2480) were obtained from the Tumor Re-
search Institute of Beijing Medical University (Beijing,
China). Dulbecco’s modified Eagle’s medium (DMEM),
Trizol reagents and Phallotoxins were obtained from
Invitrogen. Foetal bovine serum (FBS) was supplied by
Every Green Co. Ltd (Hangzhou, China). AGE-bovine
serum albumin (AGE-BSA), diphenyliodonium (DPI),
GF 109203X and BAY-117082 were purchase from
Merck. Asymmetric dimethylarginine (ADMA) stand-
ard was purchased from Sigma. Intercellular adhesion
molecule-1 (ICAM-1) ELISA kits and Griess reagents
were purchased from Jiancheng Biological Medical En-
gineering Institute (Nanjing, China). ROS detection kits
and BCA protein kits were purchased from Beyotime
Company (Jiangsu, China). Rabbit anti-human-profilin-
1 antibody was purchased from Santa Cruz. Western
blotting kits and secondary rat anti-rabbit IgG were
purchased from KPL. First strand cDNA synthesis kit
was obtained from Fermentas. The primers were
synthesised by Takara (Dalian, China). TRIzol, the
PepTag Assay for Non-Radioactive Detection of Protein
Kinase C and pGL4.32[luc2P/NF-κB-RE/Hygro] Vector
was obtained from Promega. pLNCX2-siprofilin-1 plas-
mids were synthesised by Clonetech and lipofectamine
2000 was supplied by Invitrogen.
Cell culture
HUVEC12 cells were maintained in DMEM containing
10% foetal bovine serum, 100 U/ml penicillin, and 100
μg/ml streptomycin and grown in humidified atmos-
phere of 5% CO2 in air at 37°C. HUVEC12 cells were
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well in DMEM until 70%-80% confluence. Each well
was then washed twice with phosphate-buffered saline
(PBS), and 2 ml of DMEM containing various concen-
trations of AGEs (100 μg/ml, 200 μg/ml, 400 μg/ml)
were added for different time periods (0, 6, 12, 24, 48 h).
To elucidate the potential signal pathways, DPI (antioxi-
dants, 10 μmol/L), GF 109203X (PKC inhibitor, 10
μmol/L) and BAY-117082 (NF-κB inhibitor, 5 μmol/L)
were used in the study.
RNA isolation and real-time PCR analysis
Total RNA was extracted from cells grown in a 6-well
plate using Trizol reagent and cDNA was synthesised
from 1 μg total RNA using the First-Strand Synthesis Sys-
tem for PCR according to the manufacturer’s protocol.
The primer pairs used in amplification of profilin-1 were:
forward primer, 5′- CTGTCAGGACGCGGCCATCG -3′;
reverse primer, 5′-CAGCTGGCGTGATGTTGACGA-3′.
The primer pairs of GAPDH were: forward primer, 5′-GT
CGCCAGCCGAGCCACATC-3′; reverse primer, 5′-CC
AG GCGCCCAATACGACCA-3′. The cDNA was ampli-
fied using the SYBR PCR Master mix and 0.4 μL of each
primer pair. The amplification was performed with an ini-
tial step at 95°C for 10 min, and 40 cycles of denaturation
at 95°C for 15 s, annealing at 60°C for 15 s and extension at
72°C for 15 s for profilin-1 and GAPDH. Under optimised
conditions, there was a single melting curve and no primer-
dimer formation. The copy number for each mRNA was de-
termined using a standard curve generated with external
standards of a known copy number. All amplification reac-
tions for each sample were performed in triplicate and the
results were expressed as the ratio of profilin-1 to GAPDH
mRNA.
Protein preparation and western blotting analysis
After treatment, the cells were lysed and the protein
concentrations were measured using the BCA protein
assay. The supernatants were separated using 5% SDS-
PAGE for 1.5 h and transferred onto a polyvinylidene
difluoride (PVDF) membrane followed by 2 h incuba-
tion in 5% non-fat milk in PBST (0.1% Tween 20 in
PBS) or at 4°C overnight. The blot was probed using an
antibody against rabbit anti-human-profilin-1 (1:1500)
and subsequently incubated with FITC-conjugated sec-
ondary rat anti-rabbit IgG protected from light. The sig-
nal was detected and ratios of the target protein against
β-actin control were calculated using the Odyssey Infra-
red Imaging System (LI-COR Biosciences).
Immunofluorescent staining
The formation of actin stress fibres as an index of endo-
thelial cytoskeletal reorganisation was analysed using
fluorescence microscopy. Endothelial cells on coverslipwere fixed in 3.7% formaldehyde for 10 min at room
temperature and extracted with 0.1% Triton X-100 for 5
min. Each coverslip was incubated with a rabbit anti-
human antibody against profilin-1 (1:50) and then incu-
bated with a FITC-conjugated secondary rat anti-rabbit
IgG (imaged on the green channel). F-actin in the cyto-
plasm was stained with phallotoxins (1:200) (imaged on
the red channel) in 1% BSA in TBST for 1 h. The cells
were then rinsed four times with PBS to remove excess
antibodies, and then labelled with 1% 4′,6-diamidino-2-
phenylindole (DAPI) in PBS for 5 min to visualise nuclei.
Non-immune rabbit IgG and no phallotoxins were used as
a negative control in consecutive sections. Microscopy
was performed using the IX81 FV1000 laser confocal
scanning microscope (Olympus, Japan).
Supernatant ICAM-1, NO, and ADMA detection
ICAM-1 in supernatants were detected using an ELISA
kit. The level of nitric oxide (NO) in the medium was
determined indirectly by the content of nitrite and ni-
trate using the Griess reagent, and the absorbance was
determined at 540 nm using a spectrophotometer. The
supernatants were obtained for the measurement of
ADMA content using high-performance liquid chroma-
tography (HPLC).
Intracellular ROS detecting
After the cells of each group were treated, the cell culture
medium was removed, and 1 ml 2′,7′-dichlorofluorescin
diacetate (DCFH-DA) (1:500 diluted concentration) DMEM
was added to cover the cells completely. The cells were cul-
tured for an additional 30 min. After rinsing with serum-
free DMEM three times to remove free DCFH-DA, the level
of ROS in the HUVEC12 cells was observed using the IX81
FV1000 laser confocal scanning microscope (Olympus,
Japan) with an excitation wavelength at 488 nm.
Measurement of PKC activity
Endothelial cells (5×106 to 1×107) were extracted according
to the manufacturer’s protocol. The amount of phosphory-
lated and nonphosphorylated peptide species was detected
using spectrophotometry at a length of 570 nm. The kinase
activity was quantified using the PepTag Assay for Non-
Radioactive Detection of Protein Kinase C.
Measurement of NF-κB activity
NF-κB activity in endothelial cells was detected using
an NF-κB-luciferase reporter vector (pGL4.32[luc2P/
NF-κB-RE/Hygro] vector). Briefly, 5×106 endothelial
cells were transiently co-transfected with pSV-β-galac-
tosidase and pGL4.32[luc2P/NF-κB-RE/Hygro] using
liposome-mediated transfection at a DNA/lipid ratio of
1 μg of each plasmid DNA/2 μl of Lipofectamine 2000.
The cells were allowed to recover for 24 h prior to being
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ase activity was measured using a Victor 4 multi-labelled
counter and the Luciferase Assay System kit according to
manufacturer’s instructions. The intensity of the luciferase
activity in these cells was normalised against the β-
galactosidase activity, which was used as an internal con-
trol. The luciferase activity was expressed as a fold increase.
RNA interference and cell transfection
To silence profilin-1 gene expression, pLNCX2-siprofilin-1
plasmids were transfected into HUVEC12 cells using
Lipofectamine 2000 when the cells were 70% confluent
according to the manufacturer’s protocol. The transfection
efficiency for each experiment was determined using the
percentage of the cells that expressed GFP (green fluores-
cent protein) under a fluorescent microscope (Nikon,
Japan) or by western blotting analysis and real-time PCR.
Statistical analysis
All data were expressed as the mean ± SD. The ANOVA
test was used to detect differences between groups and
the LSD or Dunnett T3 test was used for multiple com-

























































Figure 1 Effect of AGEs on the expression of profilin-1 in HUVEC12 ce
(400 μg/ml): Endothelial cells were incubated with AGEs (100 μg/ml, 200 μg/m
cells were incubated with 200 μg/ml AGEs for 6 h, 12 h, 24 h, 48 h. C: Effect o
incubated with AGEs (100 μg/ml, 200 μg/ml, 400 μg/ml) for 4 h. n=3, *P < 0.0Results
The mRNA and protein expression of profilin-1 in
endothelial cells
Compared with the control, incubation of endothelial cells
with AGEs (100 μg/ml, 200 μg/ml, 400 μg/ml) significantly
up-regulated the mRNA and protein expression of profilin-
1 at 4 h or 24 h (P<0.05, P<0.01). In addition, treatment
with AGEs at a dose of 200 μg/ml had a most robust effect
on profilin-1 gene and protein expression (Figure 1A, C),
and demonstrated up-regulation of profilin-1 protein ex-
pression in a time-dependent manner (P<0.05, P<0.01,
Figure 1B). Thus, AGEs at a dose of 200 μg/ml for 24 h
was selected for further studies. Pretreatment with DPI (10
μmol/L), GF 109203X (10 μmol/L) and BAY-117082 (5
μmol/L) significantly decreased the up-regulated mRNA
and protein expression of profilin-1 mediated by AGEs
(200 μg/ml, 24 h) (Figure 2).Endothelial cells abnormalities
In cultured endothelial cells, treatment with AGEs (200
μg/ml, 24 h) markedly increased the levels of ICAM-1 and
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Figure 2 Effect of different inhibitors on the expression of
profilin-1 induced by AGEs in endothelial cells. A: the protein
expression of profilin-1 by western blotting; B: the mRNA expression of
profilin-1 by real-time PCR. 1: control; 2: AGEs (200 μg/ml): endothelial
cells were incubated with 200 μg/ml AGEs for 24 h; 3: A+DPI (10 μM):
endothelial cells were incubated with 10 μmol/L DPI for 1 h prior to
AGEs (200 μg/ml, 24 h); 4: A+BAY-117802 (5 μM): endothelial cells were
incubated with 5 μmol/L BAY-117802 for 1 h prior to AGEs (200 μg/ml,
24 h); 5: A+GF 109203X (10 μM): endothelial cells were incubated with
10 μmol/L GF 109203X for 1 h prior to AGEs (200 μg/ml, 24 h); 6: A+si
profilin-1 (4 μg): endothelial cells were incubated with 200 μg/ml AGEs
and 4 μg pLNCX2-si profilin-1 for 4 h and then with 200 μg/ml AGEs
for 20 h; n=3, **P < 0.01 vs control, #P < 0.05 vs AGEs (200 μg/ml),
##P < 0.01 vs AGEs (200 μg/ml).
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BAY-117082 (P<0.05, P<0.01, Figure 3).
Actin stress fibre formation in endothelial cells during
stress is a commonly recognised cytoskeletal response,
which indicates reorganisation of the actin cytoskeleton
[12]. Thus, we assessed the effects of AGEs on actin
cytoskeletal redistribution using fluorescence confocal
microscopy, which enables visualisation of profilin-1
and actin filaments. As shown in Figure 4, F-actin was
well-distributed at the edge of the cytomembrane in the
control group; however, F-actin fibre morphology and
distribution showed a marked change after treatment
with AGEs. AGEs (200 μg/ml, 24 h) induced the appear-
ance of many coarse and short actin stress fibres in the
cytoplasm. Immunofluorescent staining showed that the
level of green fluorescence in the AGE treatment group
was significantly higher than the control group, further
supporting that the expression levels of profilin-1 were
up-regulated with AGE treatment. Pretreatment with
DPI, GF 109203X and BAY-117082 markedly lowered
the green fluorescent expression and decreased the for-
mation of actin stress fibre in the cytoplasm.
The protective role of profilin-1 siRNA in AGE-induced
endothelial damage
To confirm the role of profilin-1 in AGE-mediated endo-
thelial injury, we generated specific pLNCX2-siprofilin-1
plasmids to knock down the expression of profilin-1. Pre-
treatment with 4 μg pLNCX2-siprofilin-1 plasmids success-
fully knocked down the mRNA and protein expression of
profilin-1 induced by AGEs in HUVECs (P<0.01, Figure 2).
Importantly, profilin-1 siRNA blunted the endothelial in-
jury induced by AGEs (200 μg/ml, 24 h) as shown by the
significant decrease in the levels of ICAM-1 and ADMA,
and the increase in NO production (P<0.05, P<0.01,
Figure 3). Immunofluorescent staining showed that si-
lencing profilin-1 gene expression markedly decreased
the expression of profilin-1 (red fluorescence, Figure 5B)
in the cytoplasm and improved F-actin redistribution
(red fluorescence) in the presence of AGEs (Figure 5C).
Overall, these results confirmed that AGEs induced
actin cytoskeletal reorganisation and redistribution via
increasing the levels of profilin-1 in the cytoplasm.
Involvement of PKC and the NF-κB pathway in
AGE-induced endothelial injury
To explore the potential signal pathway involved in AGE-
induced endothelial injury, DPI (antioxidant), GF 109203X
(PKC inhibitor) and BAY 117082 (NF-κB inhibitor) were
incubated for 1 h prior to AGEs stimulation. These results
showed that antioxidants or blockade of the PKC or NF-κB
pathways significantly improved the endothelial abnor-
malities induced by AGEs, concomitantly with down-
regulation of profilin-1 expression (Figures 2, 3, 4). Inaddition, DPI markedly decreased the elevated levels of
ROS induced by AGEs (200 μg/ml, 24 h); however, GF
109203X and BAY-117082 showed no significant effect
on ROS formation induced by AGEs (Figure 6). Because
marked green fluorescence showed mutual interference,
the intracellular ROS levels were not determined in













































































































































































Figure 3 Effect of different inhibitors on the levels of cytokines induced by AGEs in endothelial cells. A: the levels of ICAM-1; B: the levels
of ADMA; C: the levels of NO. n=6, **P < 0.01 vs control, #P < 0.05 vs AGEs (200 μg/ml), ##P < 0.01 vs AGEs (200 μg/ml).
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DPI and BAY-117082 markedly prevented the activation
of NF-κB (P<0.05, P<0.01). However, GF 109203X had no
effect on the activity of NF-κB, and BAY-117082 had no
effect on the activity of PKC (P>0.05). Blockade of
profilin-1 expression also had no effect on the activation
of PKC and NF-κB induced by AGEs (Figure 7). These re-
sults suggested that AGEs mediated endothelial abnormal-
ities via the excess formation of ROS and subsequent
activation of the PKC and NF-κB pathways. Furthermore,
profilin-1 is the ultimate and common downstream ef-
fector in endothelial injury.
Discussion
The main findings of the present study are as follows: (1)
AGEs induced endothelial injury as shown by increasing
ADMA and ICAM levels and decreasing the synthesis of
NO, which occured concomitantly with the up-regulated
expression of profilin-1 and the rearrangement and redis-
tribution of F-actin. This was attenuated by treatment with
the antioxidant DPI, PKC inhibitor GF109203X or NF-κB
inhibitor BAY117082; (2) Knockdown of profilin-1 gene
expression attenuated AGE-induced endothelial abnormal-
ities; (3) AGEs up-regulated the expression of profilin-1 via
the excess production of ROS and subsequent activation of
PKC and NF-κB. Taken together, these findings suggested,
for the first time, that profilin-1 plays an important role inendothelial injury induced by AGEs, which may contribute
to macrovascular complications in DM.
There is accumulating evidence that AGEs formation
due to chronic hyperglycaemia has a chemical, cellular
and tissue effect in metabolic memory. AGEs have been
previously associated with the development of diabetes-
related macrovascular and microvascular complications
[13-15]. It has been recently reported that dietary AGEs
in diabetic patients or intraperitoneal injection of AGEs
in rats caused an impairment in the vascular endothe-
lium [16-18], which was prevented by treatment with
the AGE inhibitor benfotiamine [16]. Accumulation of
AGEs in the vasculature initiated a series of morpho-
logical and functional changes in endothelial cells and
induced an increase in endothelial permeability and cell
apoptosis. Moreover, it also promoted endothelial (pro-
genitor) cell migration, adhesion and focal contact for-
mation, concomitantly with the decreased synthesis of
NO and the activity of superoxide dismutase (SOD)
[10,18,19]. It is well-known that the vascular endothe-
lium is an important target of hyperglycaemic damage
and an increase in endothelial permeability to macro-
molecules results in vascular dysfunction that is associ-
ated with several pathological states, including diabetes.
Previous studies have demonstrated that the elevated
ADMA levels connected with the uncoupling of NO
synthesis contributing to endothelial dysfunction were
A+BAY-117802 (5 mol/L)





DAPI nuclei Profilin-1 F-actin Merge
Figure 4 Effect of different inhibitors on the expression of profilin-1 and the distribution of F-actin induced by AGEs in endothelial
cells. n=3. Immunofluorescence staining for profilin-1 (green), F-actin (red) and 4′,6-diamidino-2-phenylindole (DAPI) nuclei (blue). Non-immune
rabbit IgG was used as blank.
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patients [20]. Indeed, ADMA has been recognised as a
marker of endothelial dysfunction and as a risk factor of
cardiovascular diseases [21,22]. It was recently reported
that AGEs markedly increased ADMA levels in tubular
and endothelial cells via the stimulation of local ROS pro-
duction [23,24]. A great deal of studies have demonstrated
that circulating level of sICAM-1 is considered to be one
important marker of endothelial dysfunction and it was
reported that the endothelial dysfunction marked by im-
paired acetylcholine-induced endothelium-dependent re-
laxation of aortic rings and elevated levels of sICAM-1
were present in streptozocin-induced diabetic rats [25]. In
the present study, we explored the effect of AGEs on the
adverse actions in cultured endothelial cells. Consistent
with previous studies, incubation with AGEs markedly re-
duced the synthesis of NO, increased the levels of ADMA,
ICAM-1 and intracellular ROS, which was attenuated by
pretreatment with the antioxidant DPI, suggesting that ex-
ogenous AGEs directly induced endothelial injury via the
overproduction of ROS.Profilin-1, an intracellular actin-binding protein, achieves
its function via the regulation of the size, localization and
dynamics of unpolymerised actin in cells contributing to
endothelial cell contraction and vascular hyperpermeability.
Previous studies have demonstrated that cardiovascular risk
factors, such as homocysteine, LDL, ox-LDL, and oxidised
cholesterol can up-regulated the expression of profilin-1 in
cultured endothelial cells, resulting in cytoskeletal structural
remodelling [8,26,27]. Recently, it has been reported that
overexpression of profilin-1 up-regulated the expression of
ICAM-1, increased endothelial cell permeability, induced
endothelial cell apoptosis and promoted endothelial cell mi-
gration, adhesion and focal contact formation [7,9] and si-
lencing profilin-1 gene expression provided significant
protection on endothelial cells [28]. In vivo studies have
further demonstrated that profilin-1 expression was up-
regulated in endothelial cells and macrophages in athero-
sclerotic lesions in ApoE null mice, and in the aorta of
diabetic rats, and the serum levels of profilin-1 were signifi-
cantly elevated in patients with severe AS [8,29]. In
contrast, attenuated expression of profilin-1 conferred
BC
A
DAPI nuclei Profilin-1 F-actin Merge
DAPI nuclei GFP Profilin-1 Merge
DAPI nuclei GFP F-actin Merge
AGEs (200 g/ml)
A+si profilin-1 (4 g)
A+si profilin-1 (4 g)
Figure 5 Effect of profilin-1 siRNA on the expression of profilin-1 and the distribution of F-actin induced by AGEs in endothelial cells.
n=3. A: AGEs: endothelial cells were incubated with 200 μg/ml AGEs for 24 h. Immunofluorescence staining for profilin-1 (green), F-actin (red) and
DAPI nuclei (blue). B: A+si profilin-1 (4 μg): endothelial cells were incubated with 200 μg/ml AGEs and 4 μg pLNCX2-si profilin-1 for 4 h and then
with 200 μg/ml AGEs for 20 h. Immunofluorescence staining for green fluorescent protein (GFP) (green), profilin-1 (red) and DAPI nuclei (blue). C:
A+si profilin-1 (4 μg): Immunofluorescence staining for GFP (green), F-actin (red) and DAPI nuclei (blue).
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cently, Romeo et al. reported that high-fat diet (HFD) up-
regulated the expression of profilin-1 in both stromal
vascular cells and adipocytes of white adipose tissue
(WAT) and pfn heterozygote mice (PfnHet) displayed near
normalization of HFD-induced glucose intolerance and the
release of pro-inflammatory cytokines, suggesting that
profilin-1 plays an bran-new role in modulation of immunecontrol AGEs (20
A+BAY-117802 (5 M) A+GF 10920
Figure 6 Effect of different inhibitors on the levels of intracellular ROhomeostasis within the WAT microenvironment [30]. Be-
cause endothelial damage stimulated by profilin-1 in dia-
betes is surprisingly similar with that in lipid oxidation, it is
conceivable that profilin-1 may function in a common
pathway that induces vascular endothelial injuries in vascu-
lar lesions. It has been previously reported that incubation
with AGEs caused a significant increase in the permeability
of endothelial cell monolayers via significant disorganisation0 g/ml) A+DPI (10 M)
3X (10 M)

































































































































Figure 7 Effect of different inhibitors on the signaling pathways mediated by AGEs in endothelial cells. A: the activity of PKC; B: the
activity of NF-қB. n=4, *P < 0.05 vs control, **P < 0.01 vs control, #P < 0.05 vs AGEs (200 μg/ml), ##P < 0.01 vs AGEs (200 μg/ml).
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herent junctions [10,11,31-33]. However, detailed studies on
the role of profilin-1 in AGE-induced adverse actions in vas-
cular endothelial cells are lacking. In addition, the protection
offered by specifically blocking the expression of profilin-1
against AGE-induced endothelial alterations has not yet
been reported. This study found that treatment with AGEs
markedly up-regulated the mRNA and protein expression
of profilin-1, which was accompanied by the rearrange-
ment and redistribution of the cytoskeleton. However,
silencing profilin-1 expression significantly attenuated en-
dothelial injury by increasing the synthesis of NO and de-
creasing the levels of ADMA and ICAM-1. This occurred
concomitantly with the attenuation of the cytoskeletal re-
arrangement. To the best of our knowledge, this is the first
report demonstrating that AGEs up-regulated the expres-
sion of profilin-1 in vascular endothelial cells and the
silencing of profilin-1 expression induced endothelial pro-
tection against AGEs effects.
It is well known that AGEs mediate metabolic mem-
ory via its receptor RAGE to produce excess ROS, and
subsequently activates PKC and NF-κB signalling via
intracellular signalling cascades. This process induces
the expression of a variety of diabetes-related genes
[1,5]. Normalisation of the levels of mitochondrial ROS
prevented glucose-induced activation of PKC and NF-
κB, the formation of AGEs and sorbitol accumulation
[34]. It has been previously reported that AGEs induced
PKC-β translocation, extracellular signal-regulated pro-
tein kinase 1/2 and NF-κB activation in bovine retinal
endothelial cell, and pharmacological inhibition of these
signalling pathways and antioxidants abolished the
effects mediated by AGEs [35]. Substantial evidence in-
dicates that activation of PKC and NF-κB is a key bio-
chemical event implicated in the development of
diabetic vascular complications [36,37]. To elucidate
the potential signal pathway involved in endothelialinjury induced by AGEs, antioxidant DPI, PKC inhibitor
(GF 109203X) and NF-κB inhibitor (BAY-117082) were
employed. These results showed that pretreatment with
DPI, GF 109203X and BAY-117082 attenuated endothe-
lial injury, down-regulated the elevated expression of
profilin-1 and ameliorated the actin cytoskeleton re-
arrangement and redistribution induced by AGEs. Anti-
oxidant DPI markedly inhibited the formation of ROS
and activation of PKC and NF-κB signalling by AGEs.
However, blockade of the PKC and NF-κB pathways had
no significant effect on the overproduction of ROS. It
was previously reported that shear stress increased the
production of ROS and the activity of PKC in aortic
endothelial cells, and the increase in ROS production
was unaffected by GF109203X, whereas the activation
of PKC was reduced by antioxidant N-acetyl-L-cysteine
(NAC) [38]. Thus we concluded that oxidative stress trig-
gered by AGEs subsequently activated downstream NF-κB
and PKC signalling pathways. Interestingly, silencing of
profilin-1 gene expression induced endothelial protection,
but did not affect the activity of NF-κB and PKC. Thus, it
can be inferred that AGEs up-regulated the expression of
profilin-1 and caused damage in endothelial cells via the
production of excess ROS, thereby activating NF-κB and
PKC signalling pathways. Thus, we speculated that
profilin-1 functions as an ultimate and common cellular
channel in endothelial abnormalities mediated by AGEs.
In conclusion, the present study suggests, for the first
time, that profilin-1 is a downstream molecule that me-
diates endothelial injury induced by AGEs via the ROS/
PKC or ROS/NF-κB signalling pathways, and blockade
of profilin-1-mediated biological effects may help to pre-
vent endothelial injuries and vascular lesions in diabetes.
Taken together, these findings set the stage for a promin-
ent role of profilin-1 as a modulator of the actin cyto-
skeleton, which may underlie the pathology of vascular
diseases, including diabetes.
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